With exports accounting for over 65 per cent of its total turnover of Rs 100 crore, the company would be focusing on the unregulated markets including the south east Asian countries and West Asia in the current year.
Next year, as per its fresh growth strategy, the company intends to enhance its focus on semi-regulated markets such as Africa and Brazil.
Also, in post-product patent regime that comes into effect from January 2005, the company would embark on a major brand-building exercise of its prescription brand basket while the over the counter (OTC) brand portfolio would be brought under focus from the third year of the patent era. The prescription segment contributes around 78 per cent of the total turnover.
